GoodRx Releases Fourth Quarter and Full Year 2021 Financial Results
Get Alerts GDRX Hot Sheet
Join SI Premium – FREE
SANTA MONICA, Calif.--(BUSINESS WIRE)-- GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, has released its fourth quarter and full year 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com.
GoodRx management will host a conference call and webcast today at 2:00 pm. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company’s business outlook.
Fourth Quarter and Full Year 2021 Results Conference Call
Date: |
Monday, February 28, 2022 |
|||||
Time: |
2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time |
|||||
Webcast: |
https://investors.goodrx.com (live and replay) |
|||||
Dial-in number: |
(833) 614-1447 |
Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.
About GoodRx
GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over $35 billion and are one of the most downloaded medical apps over the past decade.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220228005858/en/
Investor Contact
GoodRx
Whitney Notaro
[email protected]
Press Contact
GoodRx
Lauren Casparis
[email protected]
Source: GoodRx Holdings, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Advantest Partners with OpenLight to Develop Silicon Photonics Test Solutions for High-Volume Manufacturing
- Spotlight Medical Secures IVDR CE Marking for myStage Dx, Its AI-Enabled Prognostic Test for ER+/HER2 – Early Breast Cancer
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share